메뉴 건너뛰기




Volumn 49, Issue 5, 2017, Pages 579-588

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

Author keywords

Asia; Ceftazidime avibactam; Complicated intra abdominal infection; Efficacy; Phase 3; Safety

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; MEROPENEM; METRONIDAZOLE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; THIENAMYCIN DERIVATIVE;

EID: 85017371968     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.010     Document Type: Article
Times cited : (113)

References (33)
  • 1
    • 79952420498 scopus 로고    scopus 로고
    • Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa
    • [1] Kanj, S.S., Kanafani, Z.A., Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86 (2011), 250–259.
    • (2011) Mayo Clin Proc , vol.86 , pp. 250-259
    • Kanj, S.S.1    Kanafani, Z.A.2
  • 2
    • 84879017742 scopus 로고    scopus 로고
    • Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)
    • [2] Sheng, W.H., Badal, R.E., Hsueh, P.R., Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 57 (2013), 2981–2988.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 2981-2988
    • Sheng, W.H.1    Badal, R.E.2    Hsueh, P.R.3
  • 3
    • 79952111025 scopus 로고    scopus 로고
    • Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections
    • [3] Bush, K., Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections. Crit Care, 14, 2010, 224.
    • (2010) Crit Care , vol.14 , pp. 224
    • Bush, K.1
  • 5
    • 73649114948 scopus 로고    scopus 로고
    • Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
    • [5] Solomkin, J., Mazuski, J.E., Bradley, J.S., Rodvold, K.A., Goldstein, E.J., Baron, E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 133–164.
    • (2010) Clin Infect Dis , vol.50 , pp. 133-164
    • Solomkin, J.1    Mazuski, J.E.2    Bradley, J.S.3    Rodvold, K.A.4    Goldstein, E.J.5    Baron, E.J.6
  • 6
    • 84878337468 scopus 로고    scopus 로고
    • Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections
    • [6] Solomkin, J., Ristagno, R.L., Das, A.F., Cone, J.B., Wilson, S.E., Rotstein, O.D., et al. Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis 56 (2013), 1765–1773.
    • (2013) Clin Infect Dis , vol.56 , pp. 1765-1773
    • Solomkin, J.1    Ristagno, R.L.2    Das, A.F.3    Cone, J.B.4    Wilson, S.E.5    Rotstein, O.D.6
  • 7
    • 84887157965 scopus 로고    scopus 로고
    • A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011
    • [7] Morrissey, I., Hackel, M., Badal, R., Bouchillon, S., Hawser, S., Biedenbach, D., A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 6 (2013), 1335–1346.
    • (2013) Pharmaceuticals (Basel) , vol.6 , pp. 1335-1346
    • Morrissey, I.1    Hackel, M.2    Badal, R.3    Bouchillon, S.4    Hawser, S.5    Biedenbach, D.6
  • 8
    • 85014571133 scopus 로고    scopus 로고
    • Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)
    • [8] Jean, S.S., Hsueh, P.R., SMART Asia-Pacific Group. Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 72 (2017), 166–171.
    • (2017) J Antimicrob Chemother , vol.72 , pp. 166-171
    • Jean, S.S.1    Hsueh, P.R.2
  • 9
    • 84867166640 scopus 로고    scopus 로고
    • Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions
    • [9] Tzouvelekis, L.S., Markogiannakis, A., Psichogiou, M., Tassios, P.T., Daikos, G.L., Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25 (2012), 682–707.
    • (2012) Clin Microbiol Rev , vol.25 , pp. 682-707
    • Tzouvelekis, L.S.1    Markogiannakis, A.2    Psichogiou, M.3    Tassios, P.T.4    Daikos, G.L.5
  • 10
    • 84884764949 scopus 로고    scopus 로고
    • Kinetics of avibactam inhibition against class A, C, and D β-lactamases
    • [10] Ehmann, D.E., Jahic, H., Ross, P.L., Gu, R.F., Hu, J., Durand-Reville, T.F., et al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 288 (2013), 27960–27971.
    • (2013) J Biol Chem , vol.288 , pp. 27960-27971
    • Ehmann, D.E.1    Jahic, H.2    Ross, P.L.3    Gu, R.F.4    Hu, J.5    Durand-Reville, T.F.6
  • 11
    • 79955537450 scopus 로고    scopus 로고
    • Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases
    • [11] Lagace-Wiens, P.R., Tailor, F., Simner, P., DeCorby, M., Karlowsky, J.A., Walkty, A., et al. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob Agents Chemother 55 (2011), 2434–2437.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 2434-2437
    • Lagace-Wiens, P.R.1    Tailor, F.2    Simner, P.3    DeCorby, M.4    Karlowsky, J.A.5    Walkty, A.6
  • 12
    • 82955187694 scopus 로고    scopus 로고
    • In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
    • [12] Aktas, Z., Kayacan, C., Oncul, O., In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39 (2012), 86–89.
    • (2012) Int J Antimicrob Agents , vol.39 , pp. 86-89
    • Aktas, Z.1    Kayacan, C.2    Oncul, O.3
  • 13
    • 84928893993 scopus 로고    scopus 로고
    • In vitro antibacterial activity of the ceftazidime–avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases
    • [13] Levasseur, P., Girard, A.M., Miossec, C., Pace, J., Coleman, K., In vitro antibacterial activity of the ceftazidime–avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother 59 (2015), 1931–1934.
    • (2015) Antimicrob Agents Chemother , vol.59 , pp. 1931-1934
    • Levasseur, P.1    Girard, A.M.2    Miossec, C.3    Pace, J.4    Coleman, K.5
  • 14
    • 84908271938 scopus 로고    scopus 로고
    • In vivo efficacy of humanized exposures of ceftazidime–avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates
    • [14] MacVane, S.H., Crandon, J.L., Nichols, W.W., Nicolau, D.P., In vivo efficacy of humanized exposures of ceftazidime–avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 58 (2014), 6913–6919.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 6913-6919
    • MacVane, S.H.1    Crandon, J.L.2    Nichols, W.W.3    Nicolau, D.P.4
  • 15
    • 85082221247 scopus 로고    scopus 로고
    • Prescribing information: AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use
    • Available from: [Accessed 20 August 2016]
    • [15] Actavis Inc., Prescribing information: AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494lbl.pdf, 2015 [Accessed 20 August 2016].
    • (2015)
    • Actavis Inc.1
  • 16
    • 84870399321 scopus 로고    scopus 로고
    • Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
    • [16] Vazquez, J.A., Gonzalez Patzan, L.D., Stricklin, D., Duttaroy, D.D., Kreidly, Z., Lipka, J., et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28 (2012), 1921–1931.
    • (2012) Curr Med Res Opin , vol.28 , pp. 1921-1931
    • Vazquez, J.A.1    Gonzalez Patzan, L.D.2    Stricklin, D.3    Duttaroy, D.D.4    Kreidly, Z.5    Lipka, J.6
  • 17
    • 84877123198 scopus 로고    scopus 로고
    • Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial
    • [17] Lucasti, C., Popescu, I., Ramesh, M.K., Lipka, J., Sable, C., Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68 (2013), 1183–1192.
    • (2013) J Antimicrob Chemother , vol.68 , pp. 1183-1192
    • Lucasti, C.1    Popescu, I.2    Ramesh, M.K.3    Lipka, J.4    Sable, C.5
  • 18
    • 84971578709 scopus 로고    scopus 로고
    • Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection—results from a randomised, controlled, double-blind, phase 3 program
    • [18] Mazuski, J.E., Gasink, L.B., Armstrong, J., Broadhurst, H., Stone, G.G., Rank, D., et al. Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection—results from a randomised, controlled, double-blind, phase 3 program. Clin Infect Dis 62 (2016), 1380–1389.
    • (2016) Clin Infect Dis , vol.62 , pp. 1380-1389
    • Mazuski, J.E.1    Gasink, L.B.2    Armstrong, J.3    Broadhurst, H.4    Stone, G.G.5    Rank, D.6
  • 19
    • 84995390345 scopus 로고    scopus 로고
    • Ceftazidime–avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program
    • [19] Wagenlehner, F.M., Sobel, J.D., Newell, P., Armstrong, J., Huang, X., Stone, G.G., et al. Ceftazidime–avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63 (2016), 754–762.
    • (2016) Clin Infect Dis , vol.63 , pp. 754-762
    • Wagenlehner, F.M.1    Sobel, J.D.2    Newell, P.3    Armstrong, J.4    Huang, X.5    Stone, G.G.6
  • 20
    • 84963954564 scopus 로고    scopus 로고
    • Results from REPRISE, a randomised, pathogen-directed phase 3 study of ceftazidime–avibactam or best available therapy in patients with ceftazidime-resistant complicated urinary tract infections or complicated intra-abdominal infections
    • [20] Carmeli, Y., Armstrong, J., Laud, P.J., Newell, P., Stone, G., Wardman, A., et al. Results from REPRISE, a randomised, pathogen-directed phase 3 study of ceftazidime–avibactam or best available therapy in patients with ceftazidime-resistant complicated urinary tract infections or complicated intra-abdominal infections. Lancet Infect Dis 16 (2016), 661–673.
    • (2016) Lancet Infect Dis , vol.16 , pp. 661-673
    • Carmeli, Y.1    Armstrong, J.2    Laud, P.J.3    Newell, P.4    Stone, G.5    Wardman, A.6
  • 21
    • 84976585919 scopus 로고    scopus 로고
    • Summary of product characteristics: Zavicefta
    • Available from: [Accessed 20 August 2016]
    • [21] AstraZeneca Ltd, Summary of product characteristics: Zavicefta. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf, 2016 [Accessed 20 August 2016].
    • (2016)
    • AstraZeneca Ltd1
  • 22
    • 84926365447 scopus 로고    scopus 로고
    • A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
    • [22] Baietto, L., Corcione, S., Pacini, G., Perri, G.D., D'Avolio, A., De Rosa, F.G., A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?. Curr Drug Metab 15 (2014), 581–598.
    • (2014) Curr Drug Metab , vol.15 , pp. 581-598
    • Baietto, L.1    Corcione, S.2    Pacini, G.3    Perri, G.D.4    D'Avolio, A.5    De Rosa, F.G.6
  • 23
    • 49949090275 scopus 로고    scopus 로고
    • The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies
    • [23] Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84 (2008), 417–423.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 417-423
    • Yasuda, S.U.1    Zhang, L.2    Huang, S.M.3
  • 24
    • 33646696219 scopus 로고    scopus 로고
    • Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement
    • CLSI Wayne, PA Document M100-S22
    • [24] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. 2012, CLSI, Wayne, PA Document M100-S22.
    • (2012)
    • Clinical and Laboratory Standards Institute1
  • 25
    • 0021832508 scopus 로고
    • Comparative analysis of two rates
    • [25] Miettinen, O., Nurminen, M., Comparative analysis of two rates. Stat Med 4 (1985), 213–226.
    • (1985) Stat Med , vol.4 , pp. 213-226
    • Miettinen, O.1    Nurminen, M.2
  • 26
    • 44849104852 scopus 로고    scopus 로고
    • Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study
    • [26] Lucasti, C., Jasovich, A., Umeh, O., Jiang, J., Kaniga, K., Friedland, I., Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 30 (2008), 868–883.
    • (2008) Clin Ther , vol.30 , pp. 868-883
    • Lucasti, C.1    Jasovich, A.2    Umeh, O.3    Jiang, J.4    Kaniga, K.5    Friedland, I.6
  • 27
    • 84859625873 scopus 로고    scopus 로고
    • Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial
    • [27] Qvist, N., Warren, B., Leister-Tebbe, H., Zito, E.T., Pedersen, R., McGovern, P.C., et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt) 13 (2012), 102–109.
    • (2012) Surg Infect (Larchmt) , vol.13 , pp. 102-109
    • Qvist, N.1    Warren, B.2    Leister-Tebbe, H.3    Zito, E.T.4    Pedersen, R.5    McGovern, P.C.6
  • 28
    • 84929206762 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)
    • [28] Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60 (2015), 1462–1471.
    • (2015) Clin Infect Dis , vol.60 , pp. 1462-1471
    • Solomkin, J.1    Hershberger, E.2    Miller, B.3    Popejoy, M.4    Friedland, I.5    Steenbergen, J.6
  • 29
    • 69949120498 scopus 로고    scopus 로고
    • Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections
    • [29] Solomkin, J., Zhao, Y.P., Ma, E.L., Chen, M.J., Hampel, B., Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 34 (2009), 439–445.
    • (2009) Int J Antimicrob Agents , vol.34 , pp. 439-445
    • Solomkin, J.1    Zhao, Y.P.2    Ma, E.L.3    Chen, M.J.4    Hampel, B.5
  • 30
    • 84957426156 scopus 로고    scopus 로고
    • A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime–avibactam in healthy Chinese subjects
    • [30] Li, J., Learoyd, M., Qiu, F., Zhu, L., Edeki, T., A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime–avibactam in healthy Chinese subjects. Clin Drug Investig 36 (2016), 119–126.
    • (2016) Clin Drug Investig , vol.36 , pp. 119-126
    • Li, J.1    Learoyd, M.2    Qiu, F.3    Zhu, L.4    Edeki, T.5
  • 31
    • 84937627900 scopus 로고    scopus 로고
    • Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers
    • [31] Tominaga, N., Edeki, T., Li, J., Learoyd, M., Bouw, M.R., Das, S., Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. J Infect Chemother 21 (2015), 551–558.
    • (2015) J Infect Chemother , vol.21 , pp. 551-558
    • Tominaga, N.1    Edeki, T.2    Li, J.3    Learoyd, M.4    Bouw, M.R.5    Das, S.6
  • 32
    • 84906085321 scopus 로고    scopus 로고
    • Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane–tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections
    • [32] Lucasti, C., Hershberger, E., Miller, B., Yankelev, S., Steenbergen, J., Friedland, I., et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane–tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 58 (2014), 5350–5357.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 5350-5357
    • Lucasti, C.1    Hershberger, E.2    Miller, B.3    Yankelev, S.4    Steenbergen, J.5    Friedland, I.6
  • 33
    • 85082208485 scopus 로고    scopus 로고
    • © 1g injection SPC
    • Available from: [Accessed 20 August 2016]
    • © 1g injection SPC. Available from: http://www.medicines.org.uk/emc/document.aspx?documentid=19176&docType=SPC, 2016 [Accessed 20 August 2016].
    • (2016)
    • GlaxoSmithKline1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.